Loading...

ContextVision AB (publ)

0L8Z.L•LSE
Technology
Software - Application
£4.90
£-0.02(-0.41%)

ContextVision AB (publ) (0L8Z.L) Stock Overview

Explore ContextVision AB (publ)’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B+

Score: 71.9/100

Key Financials

Market Cap379.1M
P/E Ratio25.34
EPS (TTM)N/A
ROE0.14%
Fundamental Analysis

AI Price Forecasts

1 WeekN/A
1 Month$4.58
3 Months$6.92
1 Year Target$4.49

0L8Z.L Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of ContextVision AB (publ) (0L8Z.L) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 56.92, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $4.49.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 25.34 and a market capitalization of 379.1M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Technical Indicators

56.92RSI (14)
0.00MACD
37.86ADX
Revenue Growth
-1.46%
↓ 1.46%
Profit Growth
£0.17
↓ 24.60%
EPS Growth
£0.17
↓ 23.81%
Operating Margin
12.62%
↓ 25.55%
ROE
14.07%
↓ 24.60%
Dividend Yield
0.00%
↓ 100.00%
Analyst Recommendations data is not available for 0L8Z.LAnalyst Recommendations details for 0L8Z.L are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

ContextVision AB (publ), a medical technology software company, provides image analysis and artificial intelligence software solutions to original equipment manufacturers in Asia, Europe, and the United States. The company offers image enhancement software for 2D/3D/4D ultrasound, radiography, magnetic resonance imaging (MRI), and mammography. Its products include Rivent that offers unparalleled image quality for various types of ultrasound systems for women's health, general imaging, cardiovascular, and point of care applications; VolarView, an image enhancement software for the handheld ultrasound market segment; and GOPiCE, a technology for volumetric image enhancement in real-time. The company also provides Altumira/Altumira Plus, a platform for digital radiography; and Orthopedic Package for orthopedic imaging. In addition, it offers GOPView MRI2Plus, an image enhancement solution for MRI; and INIFY Prostate Screening for digital analysis of prostate biopsies. The company was founded in 1983 and is headquartered in Stockholm, Sweden.

CEO

Gerald Potzsch

Employees

35

Headquarters

HollAendargatan 13, 2 tr, Stockholm

Founded

2017

Frequently Asked Questions

;